tickdelta
Sign in
Screener / SEC EDGAR /CIK 0001097149 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
CRLALGNILMNMTDCOOIDXX
Nasdaq Health care · Medical Devices

Align Technology ALGN

ALGN quote by TradingView
Employees
20,290
Headquarters
Tempe, AZ
CEO
Joseph Hogan
Next results
around Feb 3, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $4.0B through the costs to a net profit of $410.4M · income statement of the 10-K

14% operating margin
Revenue to Gross profit: $2.7BRevenue to Cost of revenue: $1.3BGross profit to Operating profit: $545.8MGross profit to Operating expenses: $2.2BOperating profit to Net profit: $410.4MOperating profit to Tax & other: $135.4MOperating expenses to R&D: $369.9MOperating expenses to SG&A: $1.8B Revenue: $4.0B REVENUE $4.0B +1% Y/Y Gross profit: $2.7B · 67% margin GROSS PROFIT $2.7B 67% margin · −3% Y/Y Cost of revenue: $1.3B · 33% of revenue COST OF REVENUE $1.3B 33% of revenue Operating profit: $545.8M · 14% margin OPERATING PROFIT $545.8M 14% margin · −10% Y/Y Operating expenses: $2.2B · 54% of revenue OPERATING EXPENSES $2.2B 54% of revenue Net profit: $410.4M · 10% margin NET PROFIT $410.4M 10% margin · −3% Y/Y Tax & other: $135.4M · 3% of revenue TAX & OTHER $135.4M 3% of revenue R&D: $369.9M · 9% of revenue R&D $369.9M 9% of revenue SG&A: $1.8B · 44% of revenue SG&A $1.8B 44% of revenue
Gross profit $2.7B 67% margin · −3% Y/Y
Operating profit $545.8M 14% margin · −10% Y/Y
Net profit $410.4M 10% margin · −3% Y/Y
The full income statement, year by year

ALGN among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 0.9%, above 14% of 59 peers (their median 7.2%) REVENUE GROWTH 0.9% · above 14% Gross margin: 69.1%, above 64% of 50 peers (their median 64.2%) GROSS MARGIN 69.1% · above 64% Operating margin: 14.9%, above 56% of 50 peers (their median 13.4%) OPERATING MARGIN 14.9% · above 56% Net margin: 11.8%, above 54% of 59 peers (their median 9.5%) NET MARGIN 11.8% · above 54% FCF margin: 14.5%, above 47% of 55 peers (their median 15.8%) FCF MARGIN 14.5% · above 47% Return on capital: 8.9%, above 44% of 41 peers (their median 9.2%) RETURN ON CAPITAL 8.9% · above 44%
ALGN Peer median Below the median

What changed

18 new risk paragraphs. 10-K filed Feb 27, 2026 against Feb 28, 2025.

Risk factors
18 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
11 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
4 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +10.7% vs revenue +0.9% (+9.8 pts)
  • Cash from operations $593.2M vs net income $410.4M (FY ending Dec 31, 2025)
  • Inventory -11.0% vs revenue +0.9% (-11.9 pts)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue Recognition - Determination of Standalone Selling Price of Distinct Performance Obligations in Clear Aligner Contracts
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

18 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 18 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our financial condition or results of operations.
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Geopolitical events, tariffs and trade policies, and military conflicts have and could in the future materially affect our business, financial condition and results of operations.
  3. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Tariffs or proposed tariffs, customs duties, or fees, and any retaliatory tariffs, international trade disputes, or protectionist trade measures taken in response to such tariffs may increase the cost of our products and the components or the raw materials used to make them, reduce demand for our products and adversely impact our gross…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We also face competition from traditional products and services, such as wires and brackets, which doctors have historically been able to purchase at a lower price point. We have and will likely continue to experience price-focused competition as we continue to expand into new markets, which could contribute to the commoditization of…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$3.7B$3.9B$4.0B$4.0B
Net income$361.6M$445.1M$421.4M$410.4M
Operating cash flow$568.7M$785.8M$738.2M$593.2M
Free cash flow$276.8M$608.1M$622.7M$490.8M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$4.0B ▲ 0.9% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Align Technology, Tempe, AZ · from the 10-K filed Feb 27, 2026

Align Technology, Inc. (“we,” “us,” “our,” “Align” or the “Company”) is a global medical device company primarily engaged in the design, manufacture and marketing of Invisalign® clear aligners for the treatment of malocclusions, or the misalignment of teeth, by orthodontists and general dental practitioners (“GPs”), ViveraTM retainers for retention, iTeroTM intraoral scanners and services for dentistry, and exocadTM computer-aided design and computer-aided manufacturing (“CAD/CAM”) software for dental laboratories and dental practitioners.

Headquarters
Tempe, AZ
Country
United States
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Oct 28, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had approximately 20,290 employees, a decrease of approximately 3" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALGN/export.csv") into a cell.